OBJECTIVE: Autonomic symptoms may occur frequently in diabetic and other neuropathies. There is a need to develop a simple instrument to measure autonomic symptoms in subjects with neuropathy and to test the validity of the instrument. METHODS: The Survey of Autonomic Symptoms (SAS) consists of 11 items in women and 12 in men. Each item is rated by an impact score ranging from 1 (least severe) to 5 (most severe). The SAS was tested in observational studies and compared to a previously validated autonomic scale, the Autonomic Symptom Profile (ASP), and to a series of autonomic tests. RESULTS: The SAS was tested in 30 healthy controls and 62 subjects with neuropathy and impaired glucose tolerance or newly diagnosed diabetes. An increased SAS score was associated with the previously validated ASP (rank order correlation=0.68; p<0.0001) and with quantitative measures of autonomic function: a reduced quantitative sudomotor axon reflex test sweat volume (0.31; p<0.05) and an abnormal 30:15 ratio (0.53; p<0.01). The SAS shows a high sensitivity and specificity (area under the receiver operating characteristic curve 0.828) that compares favorably with the ASP. The SAS scale domains had a good internal consistency and reliability (Cronbach α=0.76). The SAS symptom score was increased in neuropathy (95% confidence interval [CI] 2.99-4.14) compared to control (95% CI 0.58-1.69; p<0.0001) subjects. CONCLUSIONS: The SAS is a new, valid, easily administered instrument to measure autonomic symptoms in early diabetic neuropathy and would be of value in assessing neuropathic autonomic symptoms in clinical trials and epidemiologic studies.
OBJECTIVE: Autonomic symptoms may occur frequently in diabetic and other neuropathies. There is a need to develop a simple instrument to measure autonomic symptoms in subjects with neuropathy and to test the validity of the instrument. METHODS: The Survey of Autonomic Symptoms (SAS) consists of 11 items in women and 12 in men. Each item is rated by an impact score ranging from 1 (least severe) to 5 (most severe). The SAS was tested in observational studies and compared to a previously validated autonomic scale, the Autonomic Symptom Profile (ASP), and to a series of autonomic tests. RESULTS: The SAS was tested in 30 healthy controls and 62 subjects with neuropathy and impaired glucose tolerance or newly diagnosed diabetes. An increased SAS score was associated with the previously validated ASP (rank order correlation=0.68; p<0.0001) and with quantitative measures of autonomic function: a reduced quantitative sudomotor axon reflex test sweat volume (0.31; p<0.05) and an abnormal 30:15 ratio (0.53; p<0.01). The SAS shows a high sensitivity and specificity (area under the receiver operating characteristic curve 0.828) that compares favorably with the ASP. The SAS scale domains had a good internal consistency and reliability (Cronbach α=0.76). The SAS symptom score was increased in neuropathy (95% confidence interval [CI] 2.99-4.14) compared to control (95% CI 0.58-1.69; p<0.0001) subjects. CONCLUSIONS: The SAS is a new, valid, easily administered instrument to measure autonomic symptoms in early diabetic neuropathy and would be of value in assessing neuropathic autonomic symptoms in clinical trials and epidemiologic studies.
Authors: Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet Journal: Diabetes Care Date: 2003-11 Impact factor: 19.112
Authors: Andrew Grandinetti; Dominic C Chow; David M Sletten; Jared K Oyama; Andre G Theriault; Irwin J Schatz; Phillip A Low Journal: Clin Auton Res Date: 2007-08-23 Impact factor: 4.435
Authors: Amanda Peltier; A Gordon Smith; James W Russell; Kiran Sheikh; Billie Bixby; James Howard; Jonathan Goldstein; Yanna Song; Lily Wang; Eva L Feldman; J Robinson Singleton Journal: Muscle Nerve Date: 2009-04 Impact factor: 3.217
Authors: Rodica Pop-Busui; William H Herman; Eva L Feldman; Phillip A Low; Catherine L Martin; Patricia A Cleary; Barbara H Waberski; John M Lachin; James W Albers Journal: Curr Diab Rep Date: 2010-08 Impact factor: 4.810
Authors: J Robinson Singleton; Billie Bixby; James W Russell; Eva L Feldman; Amanda Peltier; Jonathan Goldstein; James Howard; A Gordon Smith Journal: J Peripher Nerv Syst Date: 2008-09 Impact factor: 3.494
Authors: Zsuzsanna Putz; Adám G Tabák; Nelli Tóth; Ildikó Istenes; Nóra Németh; Rajiv A Gandhi; Zsolt Hermányi; Katalin Keresztes; György Jermendy; Solomon Tesfaye; Péter Kempler Journal: Diabetes Care Date: 2008-10-03 Impact factor: 17.152
Authors: Esther Chicharro-Luna; Francisco José Pomares-Gómez; Ana Belen Ortega-Ávila; Ana Marchena-Rodríguez; José Francisco Javier Blanquer-Gregori; Emmanuel Navarro-Flores Journal: Int Wound J Date: 2019-11-05 Impact factor: 3.315
Authors: Krish Chandrasekaran; Muragundla Anjaneyulu; Joungil Choi; Pranith Kumar; Mohammad Salimian; Cheng-Ying Ho; James W Russell Journal: Int Rev Neurobiol Date: 2019-06-08 Impact factor: 3.230
Authors: Jessica Robinson-Papp; Alexandra Nmashie; Elizabeth Pedowitz; Emma K T Benn; Mary Catherine George; Sandeep Sharma; Jacinta Murray; Josef Machac; Sherif Heiba; Saurabh Mehandru; Seunghee Kim-Schulze; Allison Navis; Isabel Elicer; Susan Morgello Journal: AIDS Date: 2018-06-01 Impact factor: 4.177
Authors: Seockhoon Chung; Nicolaas I Bohnen; Roger L Albin; Kirk A Frey; Martijn L T M Müller; Ronald D Chervin Journal: J Clin Sleep Med Date: 2013-11-15 Impact factor: 4.062